OXPENTIFYLLINE IN ENDOTOXAEMIA

The Lancet

Volumn 334, Issue 8678-8679, 1989, Pages 1474-1477

  Zabel, P ^a   Schönharting, M M ^b   Wolter, D T ^a   Schade, U F ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTOXEMIA; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SALMONELLA;

ADULT; BODY TEMPERATURE; CLINICAL TRIALS; ENDOTOXINS; HUMANS; HYDROCORTISONE; INTERLEUKIN-6; LEUKOCYTE COUNT; MALE; PENTOXIFYLLINE; SALMONELLA; THEOBROMINE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0024785377     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(89)92929-2     Document Type: Article

References (28)

1. Tumor necrosis, cachexia, shock, and inflammation: a common mediator
2. Cachectin: a hormone that triggers acute shock and chronic cachexia
3. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
4. Passive immunization against cachectin/tumour necrosis factor protects mice from lethal effect of endotoxin
5. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumour necrosis factor
6. Endotoxin-induced pulmonary leukostasis
7. Pentoxifylline: a review of its pharmacodynamic and pharmakokinetic properties, and its therapeutic efficacy
8. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
9. Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog
10. The effect of pentoxifylline in septic shock-new pharmacologic aspects of an established drug
11. Cellular and molecular regulation of tumour necrosis factor-alpha production by pentoxifylline
12. Inhibition of the inflammatory action of interleukin 1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline
13. Production of hybridoma growth factor by human monocytes
14. Detection of circulating tumor necrosis factor after endotoxin administration
15. Mechanisms of endotoxin tolerance
16. Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha
17. Tumor necrosis factor causes increased pulmonary permeability and edema: comparison to septic acute lung injury
18. The complex pattern of cytokines in serum from patients with meningococcal septic shock
19. The biology of interleukin 1 and comparison to tumor necrosis factor
20. Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP
21. ARDS, neutrophils, and pentoxifylline
22. Effect of pentoxifylline on the phagocytotic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells
23. Pentoxifylline inhibits granulocyte and platelet activating factor
24. Attenuation of acute lung injury in septic guinea pigs by pentoxifylline
25. The effects of pentoxifylline on endotoxm-induced lung injury
26. Pentoxifylline reverses hemodynamic and histological changes associated with peritonitis in pigs